1. Home
  2. GBLI vs CGEM Comparison

GBLI vs CGEM Comparison

Compare GBLI & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBLI
  • CGEM
  • Stock Information
  • Founded
  • GBLI 2016
  • CGEM 2016
  • Country
  • GBLI United States
  • CGEM United States
  • Employees
  • GBLI N/A
  • CGEM N/A
  • Industry
  • GBLI Property-Casualty Insurers
  • CGEM Biotechnology: Pharmaceutical Preparations
  • Sector
  • GBLI Finance
  • CGEM Health Care
  • Exchange
  • GBLI Nasdaq
  • CGEM Nasdaq
  • Market Cap
  • GBLI 484.5M
  • CGEM 530.0M
  • IPO Year
  • GBLI 2003
  • CGEM 2021
  • Fundamental
  • Price
  • GBLI $30.15
  • CGEM $7.68
  • Analyst Decision
  • GBLI
  • CGEM Strong Buy
  • Analyst Count
  • GBLI 0
  • CGEM 6
  • Target Price
  • GBLI N/A
  • CGEM $28.17
  • AVG Volume (30 Days)
  • GBLI 1.5K
  • CGEM 350.6K
  • Earning Date
  • GBLI 08-06-2025
  • CGEM 08-07-2025
  • Dividend Yield
  • GBLI 4.52%
  • CGEM N/A
  • EPS Growth
  • GBLI N/A
  • CGEM N/A
  • EPS
  • GBLI 1.99
  • CGEM N/A
  • Revenue
  • GBLI $437,447,000.00
  • CGEM N/A
  • Revenue This Year
  • GBLI $7.67
  • CGEM N/A
  • Revenue Next Year
  • GBLI $7.93
  • CGEM N/A
  • P/E Ratio
  • GBLI $15.57
  • CGEM N/A
  • Revenue Growth
  • GBLI N/A
  • CGEM N/A
  • 52 Week Low
  • GBLI $26.94
  • CGEM $6.85
  • 52 Week High
  • GBLI $37.00
  • CGEM $21.01
  • Technical
  • Relative Strength Index (RSI)
  • GBLI 43.28
  • CGEM 45.96
  • Support Level
  • GBLI $30.00
  • CGEM $7.29
  • Resistance Level
  • GBLI $33.25
  • CGEM $7.94
  • Average True Range (ATR)
  • GBLI 0.63
  • CGEM 0.39
  • MACD
  • GBLI -0.26
  • CGEM -0.01
  • Stochastic Oscillator
  • GBLI 3.75
  • CGEM 61.01

About GBLI Global Indemnity Group LLC (DE)

Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: